
PHARMACEUTICAL INDUSTRY OF SYRIA

Science Market Regulation

UBIC
CONSULTING

2010



Marketing development Strategy consulting Partnership searches Information systems

Technical & Competitive Scanning - Regulations - Manufacturers

This comprehensive report is based on in-depth interviews with food companies completed by a desk review. It provides for **DECISION MAKERS** a global understanding of the sector as well as an outlook on its future.

MARKET ANALYSIS

Trends and outlook
Manufacturers profiles
Distribution
Regulation

DRUGS SEGMENTS


Antibiotics
Anti-Inflammatories
Pain relievers
Vaccines
Antitumor drugs

DISEASE CLASSES

CARDIOVASCULAR
CANCERS
DIABETES & OBESITY
DIGESTION
AGING

COUNTRIES COVERED

Syria



PHARMACEUTICAL INDUSTRY OF SYRIA

MARKET

MARKET TRENDS

DRUG SEGMENTS

GLOBAL & DETAILED
CONSUMPTION OUTLOOK

MANUFACTURERS

PHARMACEUTICAL
INDUSTRY PRESENT &
FUTURE NEEDS

RESEARCH

LACK OF LINK TO LOCAL
BASIC RESEARCH & NEED
OF FOREIGN
COOPERATION

LOCAL LEGISLATION

REGULATORY ASPECTS

INTRODUCTION

Syria produces only little active material and most of total input value is estimated to be of foreign content. While the import of drugs that are manufactured in Syria is banned, items not produced in the country can be brought in. The Government is expected to open this market to the private sector. Yet there is almost no research and development due to the lack of patent protection.

MARKET OUTLOOK

There are 52 firms producing pharmaceutical products. Syria has the largest number of pharmaceutical companies compared with any other Arab market, even though its domestic market size is smaller than many others. Private capital inflows have increased significantly in the last decade thanks to the involvement of several major industrial and trading groups in the drug industry. The two largest cities in the country, Aleppo and Damascus host the largest industrial firms.

COMPANIES

Businesses operating in the industry can be divided in three large groups :


1. Eight to 9 large firms that have adopted modern production and marketing techniques,
2. Around 25 midsized companies producing companies active in the industry mainly generic products and selling to the domestic market with only limited exports,
3. Around 25 smaller companies that have limited product ranges and often operate intermittently.



PHARMACEUTICAL INDUSTRY OF SYRIA

TABLE OF CONTENTS


METHODOLOGY	4
<i>SYNOPSIS</i>	4
<u>2- INTRODUCTION</u>	<u>5</u>
ALPHA - ALEPPO PHARMACEUTICAL INDUSTRIES LLC	10
AL FARES FOR INDUSTRY MEDICAMENT	11
ASIA PHARMACEUTICAL INDUSTRIES	12
ATTAR GROUP - MEDITERRANEAN PHARMACEUTICAL INDUSTRIES -MPI	13
AVENZOR	14
BARAKAT PHARMACEUTICAL INDUSTRIES	15
CHAOUI & PARTNERS	16
DOMINA PHARM	17
EL SAAD PHARMACEUTICAL INDUSTRIES	18
MASSOUD & BAHRI	19
MEDI PHARM	20
OUBARI &CO	21
SHIFAPHARMA	22
SYRIAN CARBONATE CO	23
THE ARABIAN MEDICAL CO - THAMECO	24
UNISHIMA	25
UNIVERSAL PHARMACEUTICAL INDUSTRIES-UNIPHARMA	26
MEGARBANE	27
CHEPHARCO CHEMICAL RAW MATERIALS	28
SABBAGH CHARABATI COMPANY	29
<u>CONCLUSION</u>	<u>30</u>




PHARMACEUTICAL INDUSTRY OF SYRIA


ORDER FORM

	Sections	Up-date 2010
Complete study	<input type="checkbox"/> All sections	• € 690

<p>Study purchase includes one year update available on-line on UBIC's Extranet</p> <p>Assistance is also available for specific questions</p> 	COMPANY _____
	Name _____ Position _____
	✉ _____
	☎ _____ Date _____
	Signature _____



UBIC CONSULTING IN THE WORLD



UBIC USA
5020 Campus Drives
NEWPORT BEACH
CA-92660
Phone: 1 702 355 8804
Fax: 1 949 752 2287
info@ubicusa.com

UBIC EUROPE
Techno-Pôle 3
3960 SIERRE
CA-92660
Phone: +41 (0) 27 456 1440
+41 (0) 27 456 1444
Fax: +41 (0) 27 456 1447
info@ubiceurope.com

UBIC IRELAND
45 Glencarraig
DUBLIN 13
CA-92660
Phone: 353 1 832 47 12
Fax: 353 1 832 12 77
ubic@ubic-consulting.com

UBIC JAPAN
2nd Floor, IBRI, 2-2
Minatojima-minamimachi,
Kobe, 650-0047 JAPAN
Phone: +81 78 303 5559
Fax: +81 50 3488 4318
japan@ubic-consulting.com